NCT00090649已完成3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study Of DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 369 人开始时间: 2004年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 369
研究概览
简要总结
To compare the antidepressant efficacy and safety of DVS-233 SR with those of placebo in adult outpatients with MDD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women 18 to 75 years of age, inclusive.
- •Sexually active individuals participating in the study must use a medically acceptable form of contraception during the study and for at least 15 days after the last dose of test article
- •Subjects must have a primary diagnosis of major depressive disorder
排除标准
- •Treatment with DVS-233 SR at any time in the past
- •Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1
- •Known hypersensitivity to venlafaxine (IR or ER)
研究者
相似试验
已完成
3 期
Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00087737Wyeth is now a wholly owned subsidiary of Pfizer369
已完成
3 期
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00072774Wyeth is now a wholly owned subsidiary of Pfizer480
已完成
3 期
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00073762Wyeth is now a wholly owned subsidiary of Pfizer375
已完成
3 期
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00063206Wyeth is now a wholly owned subsidiary of Pfizer247
已完成
3 期
Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive DisorderDepressive DisorderDepressionMajor Depressive DisorderNCT00092911Wyeth is now a wholly owned subsidiary of Pfizer244